Kiromic Biopharma (KRBPQ) AI Stock Analysis

• Market Cap: $13.27K
• Dividend Yield: N/A
• Average Volume (3M): 3.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: N/A
• EPS Growth: -4.26%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -22.86
• Shares Outstanding: 2,653,479
• 10 Day Avg. Volume: 3,734
• 30 Day Avg. Volume: 3,091
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 28 Underperform
• Price Target: ―

Kiromic Biopharma faces significant financial challenges with no revenue and increasing losses, leading to a low financial performance score. Technical indicators signal a strong bearish trend, further impacting the stock negatively. The lack of earnings results in a poor valuation score. Overall, the stock presents a high-risk investment with substantial financial and operational concerns.

Kiromic Biopharma Business Overview & Revenue Model

Company Description

Kiromic Biopharma, Inc. is a biotechnology company focused on developing immuno-oncology therapeutics. The company operates in the biotechnology sector, aiming to advance cellular therapies to treat cancer. Kiromic's core products revolve around its proprietary technology platforms, which leverage the body's immune system to target and destroy cancer cells.

How the Company Makes Money

Kiromic Biopharma makes money primarily through the development and commercialization of its immuno-oncology products. The company generates revenue by licensing its technology platforms and collaborating with pharmaceutical companies to develop new cancer therapies. Key revenue streams include milestone payments from partnerships, research funding, and eventually, product sales if their therapies receive regulatory approval. Significant factors contributing to its earnings include successful clinical trial results and strategic alliances with larger biotech or pharmaceutical companies, which can provide both financial support and expanded market reach.

Kiromic Biopharma Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Kiromic Biopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRBPQ, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and below the 200-day MA of 0.46, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.56 is Neutral, neither overbought nor oversold. The STOCH value of 71.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KRBPQ.

Kiromic Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GRI	―	$4.88M	―	-248.95%	―	―	98.45%
SCPX	―	$79.49K	―	―	―	-69.81%	88.78%
ONCO	―	$5.33M	―	-254.09%	―	-9.34%	93.84%
SLRX	―	$4.05M	-0.08	-660.37%	―	―	74.27%
PCSA	―	$15.41M	―	-212.38%	―	―	57.99%
KRBPQ	―	$13.27K	―	―	―	―	-4.26%